GLP-1 and Diabetes Management: How Semaglutide and Tirzepatide Are Changing Type 2 Diabetes Treatment

May 24, 2026

GLP-1 and Diabetes Management: How Semaglutide and Tirzepatide Are Changing Type 2 Diabetes Treatment

By Dr. Onikepe Adegbola, MD PhD — Johns Hopkins-trained physician-scientist and founder of Casa de Sante

Key Takeaways

GLP-1 receptor agonists were originally developed AS diabetes medications — the weight loss was a "side effect." Now the script has flipped: most public awareness is around weight loss, while the diabetes benefits (which are extraordinary) get less attention. For type 2 diabetics, these medications are potentially the most important advance in decades.
HbA1c reductions with GLP-1 medications: semaglutide 2.4mg reduces HbA1c by 1.5-2.0% (SUSTAIN trials). Tirzepatide at maximum dose reduces HbA1c by 2.0-2.4% (SURPASS trials). For context: getting from HbA1c 8.5% to 6.5% is the difference between diabetic complications and near-normal metabolic health.
Some patients on GLP-1 achieve diabetes REMISSION — defined as HbA1c below 6.5% without any diabetes medications. This was previously achievable only with bariatric surgery. GLP-1 medications offer a pharmaceutical path to remission for the first time.

Mechanisms of Blood Sugar Control

Glucose-Dependent Insulin Secretion

GLP-1 stimulates insulin release from pancreatic beta cells — but ONLY when blood glucose is elevated. When glucose normalizes, the insulin signal stops.
This is critical: unlike sulfonylureas (glipizide, glyburide) that stimulate insulin regardless of glucose level → hypoglycemia risk, GLP-1 has minimal hypoglycemia risk as monotherapy.
The glucose-dependent mechanism makes GLP-1 inherently safer than many older diabetes medications.

Glucagon Suppression

In type 2 diabetes, the liver overproduces glucose (via glucagon signaling) even when blood sugar is already high. GLP-1 suppresses inappropriate glucagon secretion → reduces hepatic glucose output.
This addresses one of the core metabolic defects of type 2 diabetes that metformin also targets, but through a different mechanism (complementary action).

Delayed Gastric Emptying

Slower stomach emptying → slower carbohydrate absorption → reduced postprandial (after-meal) glucose spikes. This is the mechanism that also causes the GI side effects (nausea, bloating).
For diabetics, this is a FEATURE: flattening post-meal glucose curves reduces glycemic variability, which is an independent risk factor for diabetic complications.

Tirzepatide's Dual Mechanism (GIP + GLP-1)

Tirzepatide activates BOTH GIP and GLP-1 receptors. GIP (glucose-dependent insulinotropic polypeptide) adds: enhanced insulin secretion, improved beta-cell function, and potentially better glucagon regulation.
The dual mechanism explains tirzepatide's superior HbA1c reduction compared to semaglutide (2.4% vs 1.8% reduction in head-to-head trials).

Practical Management for Diabetic GLP-1 Patients

Hypoglycemia Risk

GLP-1 alone: Very low hypoglycemia risk (glucose-dependent insulin secretion).
GLP-1 + metformin: Low hypoglycemia risk (metformin also doesn't cause hypoglycemia).
GLP-1 + sulfonylurea: MODERATE hypoglycemia risk. The sulfonylurea stimulates insulin regardless of glucose level. Sulfonylurea dose often needs reduction when adding GLP-1.
GLP-1 + insulin: SIGNIFICANT hypoglycemia risk. Insulin doses (especially basal insulin) usually need 20-30% reduction when starting GLP-1. Monitor closely.

Medication Adjustments

When GLP-1 causes significant weight loss and HbA1c improvement, other diabetes medications may become unnecessary. This is a GOOD thing — fewer medications = fewer side effects and lower cost.
Common reduction order: sulfonylurea first (highest hypoglycemia risk) → insulin dose reduction → potentially stop insulin entirely → potentially stop other oral medications.
NEVER stop diabetes medications on your own. Work with your endocrinologist to taper based on glucose monitoring data.

Blood Sugar Monitoring

During GLP-1 initiation: check fasting glucose daily and post-meal glucose 2-3x daily. The rapid improvement can surprise you — you need data to safely adjust other medications.
Continuous glucose monitors (CGMs like Libre or Dexcom) are ideal for GLP-1 initiation — they show real-time glucose trends and alert to hypoglycemia.

Gut Health and Diabetes

The Microbiome Connection

Type 2 diabetes is associated with reduced gut microbial diversity, decreased SCFA-producing bacteria, and increased gut permeability → chronic low-grade inflammation → insulin resistance.
GLP-1 may improve the microbiome indirectly through weight loss and dietary changes. But the GI side effects (especially if causing dietary restriction) can also temporarily reduce microbial diversity.
Supporting gut health during GLP-1 therapy is important for BOTH diabetes management and GI comfort.

🛒 Diabetic GLP-1 Support

Digestive Enzymes — Diabetic patients on GLP-1 face the dual challenge of medication-slowed digestion AND diabetes-related gastroparesis (present in 30-50% of long-standing diabetics). Enzymes support digestion at both levels — compensating for the delayed gastric emptying that makes meals sit heavy and the pancreatic enzyme insufficiency that can accompany diabetes.
Whey Protein — Protein is the most blood sugar-friendly macronutrient for diabetics: it stimulates insulin without spiking glucose, promotes satiety, and preserves muscle mass during weight loss. Replacing carb-heavy meals with protein shakes is a simple strategy that simultaneously improves glycemic control and supports GLP-1 weight loss.
Daily Vitamin — Diabetes depletes specific micronutrients: magnesium (involved in 300+ enzymatic reactions including insulin signaling), chromium (insulin sensitizer), B12 (depleted by metformin), and vitamin D (associated with insulin resistance when deficient). A comprehensive vitamin addresses all four simultaneously.

Medical Disclaimer: This article is for educational purposes only. Diabetic patients must work closely with their endocrinologist when starting GLP-1 therapy. NEVER adjust insulin or other diabetes medications without medical guidance. Diabetic ketoacidosis (DKA) can occur if insulin is reduced too aggressively. If you experience nausea, vomiting, abdominal pain, and confusion — check blood glucose and ketones immediately and seek emergency care. Dr. Adegbola is the founder of Casa de Sante.

Back to blog

Keto. Paleo. No Digestive Triggers. Shop Now

No onion, no garlic – no pain. No gluten, no lactose – no bloat. Low FODMAP certified.

Stop worrying about what you can't eat and start enjoying what you can. No bloat, no pain, no problem.

Our gut friendly keto, paleo and low FODMAP certified products are gluten-free, lactose-free, soy free, no additives, preservatives or fillers and all natural for clean nutrition. Try them today and feel the difference!